These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38597712)

  • 21. The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC-QTOF-MS and synthesized reference standards.
    Baginski SR; Rautio T; Nisbet LA; Lindbom K; Wu X; Dahlén J; McKenzie C; Gréen H
    J Anal Toxicol; 2023 Dec; 47(9):826-834. PubMed ID: 37747838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
    Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
    Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
    Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
    Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA.
    Ametovski A; Macdonald C; Manning JJ; Haneef SAS; Santiago M; Martin L; Sparkes E; Reckers A; Gerona RR; Connor M; Glass M; Banister SD
    ACS Chem Neurosci; 2020 Nov; 11(21):3672-3682. PubMed ID: 33054155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships of valine,
    Sparkes E; Cairns EA; Kevin RC; Lai F; Grafinger KE; Chen S; Deventer MH; Ellison R; Boyd R; Martin LJ; McGregor IS; Gerona RR; Hibbs DE; Auwärter V; Glass M; Stove C; Banister SD
    RSC Med Chem; 2022 Feb; 13(2):156-174. PubMed ID: 35308023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs.
    Sparkes E; Boyd R; Chen S; Markham JW; Luo JL; Foyzun T; Zaman H; Fletcher C; Ellison R; McGregor IS; Santiago MJ; Lai F; Gerona RR; Connor M; Hibbs DE; Cairns EA; Glass M; Ametovski A; Banister SD
    Front Psychiatry; 2022; 13():1010501. PubMed ID: 36245876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
    Alam RM; Keating JJ
    Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Characterization of a Systematic Library of Alkyl and Alicyclic Synthetic Cannabinoids Related to CUMYL-PICA, CUMYL-BUTICA, CUMYL-CBMICA, and CUMYL-PINACA.
    Janssens LK; Ametovski A; Sparkes E; Boyd R; Lai F; Maloney CJ; Rhook D; Gerona RR; Connolly M; Liu H; Hibbs DE; Cairns EA; Banister SD; Stove CP
    ACS Chem Neurosci; 2023 Jan; 14(1):35-52. PubMed ID: 36530139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of the CB
    Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
    BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018.
    Finlay DB; Nguyen T; Gamage TF; Chen S; Barrus DG; Patel PR; Thomas BF; Wiley JL; Zhang Y; Glass M
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00901. PubMed ID: 35041297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons.
    Antonides LH; Cannaert A; Norman C; NicDáeid N; Sutcliffe OB; Stove CP; McKenzie C
    Drug Test Anal; 2021 Mar; 13(3):628-643. PubMed ID: 33161649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
    Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
    Wilson CD; Hiranita T; Fantegrossi WE
    Drug Alcohol Depend; 2022 Jul; 236():109468. PubMed ID: 35643039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mastering tricyclic ring systems for desirable functional cannabinoid activity.
    Petrov RR; Knight L; Chen SR; Wager-Miller J; McDaniel SW; Diaz F; Barth F; Pan HL; Mackie K; Cavasotto CN; Diaz P
    Eur J Med Chem; 2013 Nov; 69():881-907. PubMed ID: 24125850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors.
    Noble C; Cannaert A; Linnet K; Stove CP
    Drug Test Anal; 2019 Mar; 11(3):501-511. PubMed ID: 30280499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.